On September 10, 2015 the FDA strengthened a warning about the risk of bone loss for those taking Invokana and Invokamet (canagliflozin) to treat type 2 diabetes. This is the second recent warning for Invokana which has also been linked to a risk of kidney disease and diabetic ketoacidosis.
Johnson & Johnson’s Invokana is part of a new class of type 2 diabetes drugs, SGLT2 inhibitors. Approved by the FDA in 2013, Invokana is on track to make blockbuster status this year with nearly $6M in sales in the first 6 months.
The FDA has new information based on clinical trials on bone fracture risk and decreased bone mineral density among patients taking Invokana. A 2 year study of 714 elderly diabetics found that those taking this SGLT2 drug lose more bone density in their hips and lower spine than the patients given a placebo.
While it is too early yet to determine how serious this risk may be, the FDA has recommended that doctors should consider the patients overall fracture risk before prescribing Invokana. They should also monitor the patients closely as fracture could occur as early as 12 weeks after beginning treatment with Invokana. The FDA will be evaluating whether additional warnings are needed with other drugs in the same class which includes Farxiga and Jardiance.
We are currently evaluating clients that have taken the drug Invokana and were diagnosed with kidney failure, ketoacidosis, heart attack or stroke shortly after beginning treatment. Please visit our Invokana Lawsuit page for more information and be sure to schedule your free no-obligation consultation today as there may be a time limit to file claims.